- Details
- Description
Strength:
Ponatinib equivalent to 15 mg
Composition:
Ponatinib Hydrochloride INN equivalent to Ponatinib 15 mg
Treatment:
Philadelphia chromosome-positive leukemia, including CML and Ph+ ALL
Form:
Tablet*
Brand:
Ponaxen 15
Quantity Unit:
Tablets*
Manufacturer:
Everest Pharmaceuticals Ltd.
Ponaxen 15 is an oral targeted anticancer medicine containing ponatinib 15 mg, a tyrosine kinase inhibitor (TKI) that targets BCR-ABL and other kinases. It is used for the treatment of certain Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), under specialist medical supervision.
